Ibrutinib is a Bruton tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration for the treatment of refractory mantle cell lymphoma (MCL). It has shown promising results in MCL,[...
No takes yet. Share an insight, caveat, or question.
Lee et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: